Stoke Therapeutics (NASDAQ:STOK) Insider Sells $152,687.01 in Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) insider Barry Ticho sold 4,767 shares of Stoke Therapeutics stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $32.03, for a total value of $152,687.01. Following the completion of the transaction, the insider owned 25,655 shares of the company’s stock, valued at approximately $821,729.65. This represents a 15.67% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Barry Ticho also recently made the following trade(s):

• On Monday, August 3rd, Barry Ticho sold 7,176 shares of Stoke Therapeutics stock. The shares were sold at an average price of $29.04, for a total value of $208,391.04.
• On Monday, June 1st, Barry Ticho sold 1,795 shares of Stoke Therapeutics stock. The shares were sold at an average price of $30.58, for a total value of $54,891.10.

Stoke Therapeutics Price Performance

NASDAQ:STOK opened at $31.40 on Friday. The firm has a market capitalization of $2.03 billion, a price-to-earnings ratio of -9.40 and a beta of 1.20. The business has a 50 day simple moving average of $30.94 and a 200-day simple moving average of $32.23. Stoke Therapeutics, Inc. has a 1 year low of $18.00 and a 1 year high of $40.22.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings results on Monday, August 3rd. The company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.13). The company had revenue of $9.32 million for the quarter, compared to analysts’ expectations of $4.89 million. Stoke Therapeutics had a negative net margin of 753.60% and a negative return on equity of 59.36%. As a group, analysts expect that Stoke Therapeutics, Inc. will post -3.5 earnings per share for the current fiscal year.

Analysts Set New Price Targets

STOK has been the subject of several analyst reports. BTIG Research restated a “buy” rating and issued a $39.00 target price on shares of Stoke Therapeutics in a report on Monday, May 11th. Wedbush upped their price target on shares of Stoke Therapeutics from $38.00 to $40.00 and gave the company an “outperform” rating in a report on Tuesday, August 4th. Chardan Capital reissued a “buy” rating and issued a $35.00 price objective on shares of Stoke Therapeutics in a research report on Tuesday, August 4th. Guggenheim reissued a “buy” rating and issued a $60.00 price objective on shares of Stoke Therapeutics in a research note on Tuesday, August 4th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Stoke Therapeutics in a research report on Friday, August 7th. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $43.00.

Institutional Trading of Stoke Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in STOK. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Stoke Therapeutics by 12.1% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 65,228 shares of the company’s stock valued at $2,134,000 after purchasing an additional 7,043 shares during the period. Wellington Management Group LLP increased its stake in Stoke Therapeutics by 13.7% in the 2nd quarter. Wellington Management Group LLP now owns 3,519,301 shares of the company’s stock worth $115,152,000 after buying an additional 423,601 shares during the period. Palo Alto Investors LP purchased a new position in Stoke Therapeutics in the 2nd quarter worth about $2,769,126,000. Capstone Investment Advisors LLC bought a new stake in Stoke Therapeutics during the 2nd quarter valued at about $314,000. Finally, Seven Fleet Capital Management LP bought a new stake in Stoke Therapeutics during the 2nd quarter valued at about $255,353,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.